Johnson & Johnson (JNJ) Intangibles (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Intangibles came in at $48.2 billion in Q2 2026, down 3.22% year-over-year from $49.8 billion in Q2 2025, and down 1.7% quarter-over-quarter from $49.1 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Intangibles (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Intangibles across 18 years of filings, most recently posting $48.2 billion for Q2 2026.
- In Q2 2026, Intangibles fell 3.22% year-over-year to $48.2 billion; the TTM figure through Jun 2026 stood at $48.2 billion (down 3.22% YoY), while the FY2025 annual figure was $50.4 billion, up 33.99% from the prior year.
- Intangibles came in at $48.2 billion for Q2 2026 at Johnson & Johnson, down from $49.1 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $50.4 billion in Q4 2025 to a low of $34.2 billion in Q4 2023.
- Average Intangibles over 5 years is $42.6 billion, with a median of $42.4 billion recorded in 2022.
- Year-over-year, Intangibles slipped 27.74% in 2024 and jumped 33.99% in 2025.
- Over 5 years, Intangibles stood at $40.3 billion in 2022, then dropped by 15.27% to $34.2 billion in 2023, then rose by 10.07% to $37.6 billion in 2024, then jumped by 33.99% to $50.4 billion in 2025, then retreated by 4.31% to $48.2 billion in 2026.
- Per Business Quant data, the three most recent Intangibles figures were $48.2 billion in Q2 2026, $49.1 billion in Q1 2026, and $50.4 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 47.05 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 17.39 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 30.64 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 63.28 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 60.96 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 103.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 48.23 Bn |
| Mar 29, 2026 | 49.06 Bn |
| Dec 28, 2025 | 50.40 Bn |
| Sep 28, 2025 | 48.74 Bn |
| Jun 29, 2025 | 49.84 Bn |
| Mar 30, 2025 | 36.76 Bn |
| Dec 29, 2024 | 37.62 Bn |
| Sep 29, 2024 | 39.49 Bn |
| Jun 30, 2024 | 39.73 Bn |
| Mar 31, 2024 | 34.29 Bn |
| Dec 31, 2023 | 34.18 Bn |
| Oct 1, 2023 | 35.02 Bn |
| Jul 2, 2023 | 46.25 Bn |
| Apr 2, 2023 | 47.45 Bn |
| Jan 1, 2023 | 38.49 Bn |
| Oct 2, 2022 | 40.34 Bn |
| Jul 3, 2022 | 42.41 Bn |
| Apr 3, 2022 | 44.42 Bn |
| Jan 2, 2022 | 46.39 Bn |
| Oct 3, 2021 | 47.78 Bn |